Hypericin affects cancer side populations via competitive inhibition of BCRP.
Vargová J, Mikeš J, Jendželovský R, Mikešová L, Kuchárová B, Čulka Ľ, Fedr R, Remšík J, Souček K, Kozubík A, Fedoročko P.
Vargová J, et al. Among authors: kozubik a.
Biomed Pharmacother. 2018 Mar;99:511-522. doi: 10.1016/j.biopha.2018.01.074. Epub 2018 Feb 20.
Biomed Pharmacother. 2018.
PMID: 29665654